Sickle Cell Disease (SCD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Sickle cell disease (SCD) is a group of inherited red blood cell disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disease have atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.

Etiology-

Mutations in the HBB gene cause sickle cell disease. The HBB gene provides instructions for making beta-globin. Various versions of beta-globin result from different mutations in the HBB gene. One HBB gene mutation produces an abnormal version of beta-globin known as hemoglobin S (HbS). Other mutations in the HBB gene lead to different bizarre versions of beta-globin, such as hemoglobin C (HbC) and hemoglobin E (HbE). HBB gene mutations can also result in a shallow level of beta-globin; this abnormality is called beta-thalassemia.

 

Epidemiology-

Sickle cell disease is the most common inherited blood disorder in the United States, affecting 100,000 Americans. The disease is estimated to occur in 1 in 500 African Americans and 1 in 1,000 to 1,400 Hispanic Americans.

 

The competitive landscape of Sickle Cell Disease (SCD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Sickle Cell Disease (SCD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sickle Cell Disease (SCD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Sickle Cell Disease (SCD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          VIT-2763          Vifor (International) Inc. Phase 2

2          SHP655            Shire    Phase 1

3          CTX001            Vertex Pharmaceuticals Incorporated     Phase 1/2

4          Rivipansel         GlycoMimetics Incorporated       Phase 3

5          GPH101           Graphite Bio, Inc.          Phase 1/2

6          FT-4202            Forma Therapeutics, Inc.           Phase 2/3

7          Mitapivat           Agios Pharmaceuticals, Inc.       Phase 2/3

8          IMR-687           Bioverativ, a Sanofi company     Phase 2

9          SANGUINATE   Prolong Pharmaceuticals           Phase 2

10        Hydroxyurea     Nova Laboratories Limited         Phase 2

Continued